-

MTF Biologics’ SomaGen® Meshed and Leneva® Allografts Receive American Podiatric Medical Association Seal of Approval

APMA Seal of Approval signals to physicians and clinicians that MTF Biologics® tissues are beneficial to foot health

EDISON, N.J.--(BUSINESS WIRE)--MTF Biologics® has received the coveted American Podiatric Medical Association (APMA) Seal of Approval for two MTF Biologics Wound Care tissues, SomaGen® Meshed, Allograft Dermal Matrix and Leneva®, Allograft Adipose Matrix. To receive the seal, both tissues were reviewed by a panel of experienced APMA podiatric physicians.

The APMA Seal of Approval is granted to products that are beneficial to foot health. Companies must provide comprehensive information on each product: objective data from clinical and/or laboratory studies, intended use, patents, composition, and evidence of quality control. A detailed review is conducted by each committee member, and a recommendation is then sent to the APMA Board of Trustees, which may either accept or reject the recommendation.

"Receiving the APMA Seal of Approval will give podiatrists and clinicians continued confidence that SomaGen Meshed and Leneva are revolutionary and life-changing foot health tissues forms,” said Kim Rounds, Vice President and General Manager, MTF Biologics’ Wound Care Franchise. "MTF Biologics is committed to saving and healing lives by providing the highest quality tissue forms. We are proud to have the APMA Seal of Approval awarded to SomaGen Meshed and Leneva.”

“The APMA Seal of Approval is awarded only to the top podiatric products after a rigorous scientific review indicating they meet specific standards,” said APMA Executive Director and CEO James R. Christina, DPM. “MTF Biologics SomaGen Meshed and Leneva have received our coveted Seal of Approval in recognition of their benefits in healing complex and chronic wounds.”

SomaGen Meshed is an acellular human reticular dermal allograft with a unique meshed design that provides a scaffold to support the treatment of a variety of complex wounds. SomaGen Meshed, and its biocompatible design, provides immediate wound coverage without the need for autologous skin grafting, lowering costs and saving time without compromising patient outcomes.

Leneva is a first-of-its-kind human adipose tissue for replacement of damaged or inadequate adipose tissue matrix. As an all-natural extracellular matrix, Leneva may also be used for the reinforcement or supplemental support in underlying adipose tissue matrix as the result of damage or naturally occurring defects.

MTF Biologics is committed to offering highly advanced, safe, clinically proven, and cost-effective allograft solutions for chronic and complex wounds. SomaGen® Meshed and Leneva® join MTF Biologics’ Wound Care tissues AmnioBand® Membrane, AmnioBand® Viable, AmnioBand® Particulate and AlloPatch® Pliable in attaining the prestigious APMA Seal.

About MTF Biologics

MTF Biologics is a global nonprofit organization that saves and heals lives by advancing tissue and organ donation, transplantation, and research. We provide unmatched service, resources, and expertise to donors and their loved ones who give the gift of life, people who depend on tissue and organ transplants, healthcare providers, and clinicians and scientists. Our subsidiary, The International Institute for the Advancement of Medicine (IIAM), honors donors of non-transplantable organs by providing their gifts to the medical research community to combat and cure diseases. Our subsidiary, Statline, provides specialized communications and technology expertise to organ, tissue, and eye procurement organizations, as well as the hospitals and patients that they serve. Our sister organization, The German Institute for Cell and Tissue Transplantation (Deutsches Institute for Zell-und Gewebeersatz – DIZG) expands our reach to patients across the globe. For more information, visit www.mtfbiologics.org.

About the American Podiatric Medical Association

Founded in 1912, the American Podiatric Medical Association (APMA), headquartered in Bethesda, MD, is the leading resource for foot and ankle health information. Currently, the organization represents a vast majority of the estimated 15,000 podiatrists in the country. In addition to the national headquarters, APMA boasts 53 state component locations throughout the United States and its territories, as well as affiliated societies. For more, visit www.apma.org.

Contacts

Kate Raley, 615-610-0202 or kate.raley@finnpartners.com

MTF Biologics


Release Versions

Contacts

Kate Raley, 615-610-0202 or kate.raley@finnpartners.com

More News From MTF Biologics

MTF Biologics’ AmnioBand® Membrane and AlloPatch® Pliable Confirmed as Covered Under Updated CMS Local Coverage Determinations

EDISON, N.J.--(BUSINESS WIRE)--MTF Biologics, a global nonprofit organization that saves and heals lives by honoring donated gifts and advancing the science of tissue transplantation, today announced that two of its aseptically processed allografts without terminal irradiation, AmnioBand® Membrane, an allograft placental matrix, and AlloPatch® Pliable an allograft dermal matrix, will remain among the 18 tissues covered under the newly updated Medicare Local Coverage Determinations (LCDs) for sk...

MTF Biologics and Kolosis BIO Launch Two New Allografts to Advance Cardiac Surgery

EDISON, N.J. & SALT LAKE CITY--(BUSINESS WIRE)--MTF Biologics, a global nonprofit organization that saves and heals lives by advancing tissue and organ donation, transplantation, and research, and Kolosis BIO (Kolosis), a premier provider of biologic solutions, today announced they have partnered to bring two innovative allograft tissues to cardiac surgeons: ATLAS™ Sternal Repair Matrix for sternal fusion and IKON™ Allograft Surgical Matrix for soft tissue repair in high-risk patients. These hi...

MTF Biologics Completes First Implantation of FlexHD® Pliable in Milestone Breast Reconstruction Clinical Trial

EDISON, N.J.--(BUSINESS WIRE)--MTF Biologics, a global nonprofit organization that saves and heals lives by advancing tissue and organ donation, transplantation, and research, today announced the successful implantation of FlexHD® Pliable in the first patient enrolled in its Investigational Device Exemption (IDE) clinical study for pre-pectoral breast reconstruction. This milestone pivotal study (SHAPE) aims to evaluate the safety and effectiveness of FlexHD® Pliable in implant-based breast rec...
Back to Newsroom